A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Parkinson's Disease
Interventions
DRUG

AZD3241 300 mg BID

The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.

DRUG

AZD3241 600 mg BID

The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.

DRUG

Placebo

Placebo to AZD3241 BID

Trial Locations (13)

Unknown

Research Site, Birmingham

Research Site, Long Beach

Research Site, New Haven

Research Site, Atlantis

Research Site, Boca Raton

Research Site, Orlando

Research Site, Sunrise

Research Site, Tampa

Research Site, Kansas City

Research Site, Bingham Farms

Research Site, Omaha

Research Site, Lawrenceville

Research Site, Marlton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY